Legal & General Group Plc Takes $8.44 Million Position in ICU Medical, Inc. $ICUI

Legal & General Group Plc bought a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 57,596 shares of the medical instruments supplier’s stock, valued at approximately $8,444,000. Legal & General Group Plc owned 0.23% of ICU Medical at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of ICU Medical during the fourth quarter worth $58,083,000. Kirr Marbach & Co. LLC IN raised its position in ICU Medical by 18.4% during the 1st quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock worth $5,702,000 after purchasing an additional 6,863 shares during the last quarter. F m Investments LLC lifted its holdings in ICU Medical by 33.3% during the 4th quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock worth $6,637,000 after buying an additional 11,608 shares during the period. Thrivent Financial for Lutherans lifted its holdings in ICU Medical by 1,604.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after buying an additional 285,648 shares during the period. Finally, Reinhart Partners LLC. bought a new stake in shares of ICU Medical in the 2nd quarter valued at about $46,148,000. 96.10% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ICUI. Piper Sandler increased their price target on ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Jefferies Financial Group raised shares of ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. Raymond James Financial reiterated a “strong-buy” rating and set a $200.00 price objective on shares of ICU Medical in a research report on Friday, August 7th. Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Finally, KeyCorp boosted their target price on shares of ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $192.80.

ICU Medical Price Performance

ICU Medical stock opened at $170.81 on Wednesday. The stock has a market capitalization of $4.27 billion, a price-to-earnings ratio of 144.75, a PEG ratio of 2.19 and a beta of 0.75. ICU Medical, Inc. has a 52-week low of $112.50 and a 52-week high of $192.85. The stock’s 50 day moving average price is $166.08 and its two-hundred day moving average price is $144.35. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The company had revenue of $547.88 million during the quarter, compared to analyst estimates of $533.44 million. During the same quarter in the previous year, the business posted $2.10 EPS. ICU Medical’s revenue for the quarter was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, equities analysts predict that ICU Medical, Inc. will post 7.19 earnings per share for the current year.

Insider Activity at ICU Medical

In other ICU Medical news, VP Daniel Woolson sold 5,417 shares of ICU Medical stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $181.33, for a total value of $982,264.61. Following the completion of the sale, the vice president directly owned 17,062 shares of the company’s stock, valued at approximately $3,093,852.46. The trade was a 24.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Ben Sousa sold 2,250 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total transaction of $401,220.00. Following the transaction, the insider owned 3,076 shares in the company, valued at $548,512.32. This represents a 42.25% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 16,974 shares of company stock valued at $3,085,844. 2.10% of the stock is currently owned by company insiders.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.